TY  - GEN
AU  - Rockstroh,Jürgen K
AU  - DeJesus,Edwin
AU  - Henry,Keith
AU  - Molina,Jean-Michel
AU  - Gathe,Joseph
AU  - Ramanathan,Srinivasan
AU  - Wei,Xuelian
AU  - Plummer,Andrew
AU  - Abram,Michael
AU  - Cheng,Andrew K
AU  - Fordyce,Marshall W
AU  - Szwarcberg,Javier
TI  - A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results
SN  - 1944-7884
PY  - 2013///1018
KW  - Adenine
KW  - analogs & derivatives
KW  - Adult
KW  - Alanine Transaminase
KW  - blood
KW  - Anti-HIV Agents
KW  - therapeutic use
KW  - Aspartate Aminotransferases
KW  - Atazanavir Sulfate
KW  - Bilirubin
KW  - Bone Density
KW  - drug effects
KW  - Carbamates
KW  - Cobicistat
KW  - Confidence Intervals
KW  - Creatinine
KW  - Deoxycytidine
KW  - Double-Blind Method
KW  - Drug Combinations
KW  - Emtricitabine
KW  - Female
KW  - HIV Infections
KW  - HIV-1
KW  - genetics
KW  - Humans
KW  - Male
KW  - Oligopeptides
KW  - Organophosphonates
KW  - Pyridines
KW  - Quinolones
KW  - RNA, Viral
KW  - Ritonavir
KW  - Tenofovir
KW  - Thiazoles
KW  - Triglycerides
N1  - Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1097/QAI.0b013e318286415c
ER  -